189 related articles for article (PubMed ID: 25964965)
1. Iixisenatide. Wait for conclusive results on complications of diabetes.
Prescrire Int; 2014 Oct; 23(153):234-5. PubMed ID: 25964965
[TBL] [Abstract][Full Text] [Related]
2. Hypoglycaemic therapy in type 2 diabetes. Part I. Metformin is the only glucose-lowering drug known to prevent complications of diabetes.
Prescrire Int; 2015 Apr; 24(159):103-6. PubMed ID: 25941708
[TBL] [Abstract][Full Text] [Related]
3. Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus.
Niedermier V; Ayers G; Springer S
Am Fam Physician; 2017 Aug; 96(4):257-258. PubMed ID: 28925668
[No Abstract] [Full Text] [Related]
4. Optimizing treatment for patients with diabetes mellitus: glycemic and nonglycemic effects.
Shubrook JH
J Am Osteopath Assoc; 2011 Jul; 111(7 Suppl 5):Sii-1. PubMed ID: 21928545
[No Abstract] [Full Text] [Related]
5. Divergent effects of various diabetes drugs on cardiovascular prognosis.
Bell DS; Patil HR; O'Keefe JH
Rev Cardiovasc Med; 2013; 14(2-4):e107-22. PubMed ID: 24448252
[TBL] [Abstract][Full Text] [Related]
6. Novo Nordisk incretin and Cardiovascular Summit, Durban, June 2013.
Wagenaar P
Cardiovasc J Afr; 2013 Sep; 24(8):340. PubMed ID: 24240386
[No Abstract] [Full Text] [Related]
7. Diabetes: glycated hemoglobin is a marker of diabetes and CVD risk.
Wareham NJ; Pfister R
Nat Rev Cardiol; 2010 Jul; 7(7):367-8. PubMed ID: 20577298
[TBL] [Abstract][Full Text] [Related]
8. Are We There Yet?
Tsai A
Diabetes Forecast; 2016; 69(1):52-7. PubMed ID: 26983288
[No Abstract] [Full Text] [Related]
9. Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence.
Rodríguez-Gutiérrez R; Montori VM
Circ Cardiovasc Qual Outcomes; 2016 Sep; 9(5):504-12. PubMed ID: 27553599
[TBL] [Abstract][Full Text] [Related]
10. Safety of antidiabetes medications: An update.
Bailey CJ
Clin Pharmacol Ther; 2015 Aug; 98(2):185-95. PubMed ID: 25820533
[TBL] [Abstract][Full Text] [Related]
11. [Diabetes mellitus--diagnosis and blood glucose control].
Elke B; Käser L; Berneis K; Spinas G; Battegay E
Praxis (Bern 1994); 2008 May; 97(10):529-37; quiz 538-9. PubMed ID: 18595368
[No Abstract] [Full Text] [Related]
12. Diabetes management: More than just cardiovascular risk?
Zimmerman RS; Pantalone KM
Cleve Clin J Med; 2014 Nov; 81(11):672-6. PubMed ID: 25368217
[No Abstract] [Full Text] [Related]
13. Age appropriate: Should seniors keep very tight glucose control? That's up for debate.
Wahowiak L
Diabetes Forecast; 2013 Aug; 66(8):32-3. PubMed ID: 23967522
[No Abstract] [Full Text] [Related]
14. Diabetes Management and Cardiovascular Risk: Are SGLT-2 Inhibitors the Safest?
Swislocki AL; Jialal I
Metab Syndr Relat Disord; 2016 Feb; 14(1):3-6. PubMed ID: 26677930
[TBL] [Abstract][Full Text] [Related]
15. Diabetes: Time for reconciliation between cardiologists and diabetologists.
Scheen AJ
Nat Rev Cardiol; 2016 Sep; 13(9):509-10. PubMed ID: 27411401
[No Abstract] [Full Text] [Related]
16. Glycemic control and cardiovascular mortality.
Riddle MC
Curr Opin Endocrinol Diabetes Obes; 2011 Apr; 18(2):104-9. PubMed ID: 21522000
[TBL] [Abstract][Full Text] [Related]
17. Exenatide: excessive weight loss.
Prescrire Int; 2011 Jan; 20(112):17. PubMed ID: 21462789
[No Abstract] [Full Text] [Related]
18. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
Seufert J; Gallwitz B
Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
[TBL] [Abstract][Full Text] [Related]
19. Insulin Innovations.
Curry A
Diabetes Forecast; 2015; 68(4):38-43. PubMed ID: 26374923
[No Abstract] [Full Text] [Related]
20. [Lixisenatide (Lyxumia), subcutaneous].
J Pharm Belg; 2014 Jun; (2):57-9. PubMed ID: 25055456
[No Abstract] [Full Text] [Related]
[Next] [New Search]
